These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31733426)

  • 21. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
    Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
    BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    Pfeuffer S; Ruck T; Pul R; Rolfes L; Korsukewitz C; Pawlitzki M; Wildemann B; Klotz L; Kleinschnitz C; Scalfari A; Wiendl H; Meuth SG
    J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):1007-1013. PubMed ID: 33712515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Alemtuzumab therapy 2017].
    Biernacki T; Bencsik K; Sandi D; Vécsei L
    Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
    Akgün K; Kretschmann N; Haase R; Proschmann U; Kitzler HH; Reichmann H; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e555. PubMed ID: 31119188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
    Kvistad SAS; Burman J; Lehmann AK; Tolf A; Zjukovskaja C; Melve GK; Bø L; Torkildsen Ø
    J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):844-848. PubMed ID: 35508373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
    Massey J; Barnett Y; Curnow J; Sutton I
    Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.
    Brecl Jakob G; Barun B; Gomezelj S; Gabelić T; Šega Jazbec S; Adamec I; Horvat Ledinek A; Rot U; Krbot Skorić M; Habek M
    Neurol Sci; 2021 Nov; 42(11):4591-4597. PubMed ID: 33660157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies.
    Buonomo AR; Viceconte G; Zappulo E; Maraolo AE; Russo CV; Carotenuto A; Moccia M; Gentile I
    Expert Opin Drug Saf; 2021 Oct; 20(10):1237-1246. PubMed ID: 34310251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
    Keller CW; Ruck T; McHugh D; Pfeuffer S; Gross CC; Korsukewitz C; Melzer N; Klotz L; Meuth SG; Münz C; Nimmerjahn F; Wiendl H; Lünemann JD
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2586-2594. PubMed ID: 31682087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
    J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
    Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
    J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
    Kim H; Lee EJ; Kim SK; Kim KK; Lim YM
    Mult Scler Relat Disord; 2019 May; 30():247-251. PubMed ID: 30849681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion.
    Tzartos JS; Valsami S; Tzanetakos D; Stergiou C; Dandoulaki M; Barbarousi D; Psimenou E; Velonakis G; Stefanis L; Kilidireas K
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32241823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.